A former Novo Nordisk director, who helped develop the GLP‑1 drugs Wegovy and Ozempic, says that simple dietary changes can stimulate the body’s own GLP‑1 production. By increasing vegetable intake and cutting ultra‑processed foods, he claims people can achieve similar appetite‑suppressing effects without injections.

Dietary tweaks that raise GLP‑1, according to the ex‑Novo director

According to the former research chief, boosting GLP‑1 naturally hinges on two actions: eating more vegetables and fiber, and reducing ultra‑processed foods (UPFs). He explains that L‑cells lining the gut release GLP‑1 when they encounter specific nutrients, especially those high in fiber. This physiological response mirrors the mechanism of semaglutide, the active ingredient in Ozempic and Wegovy.

Why the gut’s L‑cells matter for weight control

The source notes that L‑cells are scattered along the 26‑foot gastrointestinal tract and act as senosrs, releasing not only GLP‑1 but also PYY and GLP‑2. These hormones collectively lower blood sugar, curb appetite, and improve gut barrier function. by targeting these cells with the right foods, the ex‑director argues that individuals can tap into a “natural injection” that supports metabolic health.

Cost comparison: $15‑a‑month diet vs $1,000‑a‑year injections

He highlights that the dietary approach costs “a fraction of the cost” of prescription GLP‑1 drugs, which can exceed $1,000 annually in the United States. While the article does not provide exact figures for the diet, the implication is that a modest increase in fresh produce and reduction of processed snacks can be achieved on a typical grocery budget .

Who still needs prescription GLP‑1 drugs?

The former Novo Nordisk scientist avoids taking a stance on eligibility, noting that “that is between doctor and patient.” However, he acknowledges that doctors are seeing a surge of patients demanding injections, sometimes based on peer pressure rather than medical necessity.

Unverified claims and missing data

While the diet plan is described as “research‑backed,” the source does not cite specific clinical trials comparing its efficacy to semaglutide. It also lacks quantitative outcomes—such as average weight loss or hormone level changes—leaving readers without a clear benchmark for success.